PwC's Roel van den Akker says pharma M&A ran beyond expectations in the first half of 2026, with dealmaking potentially on pace to hit $300 billion in H2. Pharmaceutical Commerce recently checked in ...

In this week's Pharma Pulse, CVS Caremark settles with the FTC over rebates and TrumpRx, Germany more than doubles its drug rebate, and the FDA proposes a registration rule. Welcome to Pharma Pulse, a ...

Traditional wholesaler-centric, pallet-based logistics is giving way to integrated, commercialization-aligned models that manage order-to-cash complexity and optimize gross-to-net outcomes. AI ...

Specialty medicines comprise ~75% of ~7,000 pipeline assets, with nearly 180 advanced therapies expected by 2030, accelerating demand for scalable, operationally sustainable distribution models.

Embedding access tools at prescribing reduces manual enrollment, portal switching, and late activation, enabling faster benefits verification, prior authorization initiation, affordability support, ...

In this Dedicated Dialogue episode, Adam Fox, Chief Quality & Regulatory Affairs Officer of Cryoport Systems, explores how escalating regulatory expectations and patient-centric risk considerations ...

A fixed 15.5% manufacturer rebate on patented branded drugs replaces a proposed variable, expenditure-linked mechanism after coordinated industry pressure and threats to curtail German investment and ...

Beijing’s regulations effectively penalize compliance with US/EU/UK sanctions, export controls, and forced-labor regimes, converting routine supplier-management actions into potential retaliatory ...

Pairing Tennr referral intake and documentation automation with TailorMed affordability tooling is designed to surface access barriers earlier and shorten time-to-therapy for infusion and specialty ...

Supply-chain objectives should explicitly prioritize product protection, traceability for recalls/loss, circularity, and compatibility with automated material handling systems. Key KPIs include system ...

Tech-enabled pharmacies reflect the reality of the GLP-1 landscape: patient success depends on more than a prescription. With ...